163 related articles for article (PubMed ID: 27604270)
41. Human UDP-glucuronosyltransferase 1A1 is the primary enzyme responsible for the N-glucuronidation of N-hydroxy-PhIP in vitro.
Malfatti MA; Felton JS
Chem Res Toxicol; 2004 Aug; 17(8):1137-44. PubMed ID: 15310245
[TBL] [Abstract][Full Text] [Related]
42. Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform.
Ma L; Sun J; Peng Y; Zhang R; Shao F; Hu X; Zhu J; Wang X; Cheng X; Zhu Y; Wan P; Feng D; Wu H; Wang G
Drug Metab Dispos; 2012 Apr; 40(4):734-41. PubMed ID: 22238289
[TBL] [Abstract][Full Text] [Related]
43. Identification and characterization of human UDP-glucuronosyltransferases responsible for the in-vitro glucuronidation of arctigenin.
Xin H; Xia YL; Hou J; Wang P; He W; Yang L; Ge GB; Xu W
J Pharm Pharmacol; 2015 Dec; 67(12):1673-81. PubMed ID: 26407805
[TBL] [Abstract][Full Text] [Related]
44. UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics.
Wen Z; Tallman MN; Ali SY; Smith PC
Drug Metab Dispos; 2007 Mar; 35(3):371-80. PubMed ID: 17151191
[TBL] [Abstract][Full Text] [Related]
45. Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid.
Uchaipichat V; Mackenzie PI; Guo XH; Gardner-Stephen D; Galetin A; Houston JB; Miners JO
Drug Metab Dispos; 2004 Apr; 32(4):413-23. PubMed ID: 15039294
[TBL] [Abstract][Full Text] [Related]
46. Transcriptional regulation of human UDP-glucuronosyltransferase genes.
Hu DG; Meech R; McKinnon RA; Mackenzie PI
Drug Metab Rev; 2014 Nov; 46(4):421-58. PubMed ID: 25336387
[TBL] [Abstract][Full Text] [Related]
47. Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases.
Uchaipichat V; Mackenzie PI; Elliot DJ; Miners JO
Drug Metab Dispos; 2006 Mar; 34(3):449-56. PubMed ID: 16381668
[TBL] [Abstract][Full Text] [Related]
48. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes.
Linnet K
Hum Psychopharmacol; 2002 Jul; 17(5):233-8. PubMed ID: 12404680
[TBL] [Abstract][Full Text] [Related]
49. Structure-inhibition relationship of podophyllotoxin (PT) analogues towards UDP-glucuronosyltransferase (UGT) isoforms.
Qi JQ; Cao YF; Sun XY; Hong M; Fang ZZ; Meng DL; Sun DX
Pharmazie; 2015 Apr; 70(4):239-43. PubMed ID: 26012253
[TBL] [Abstract][Full Text] [Related]
50. UDP glucuronosyltransferase mRNA levels in human liver disease.
Congiu M; Mashford ML; Slavin JL; Desmond PV
Drug Metab Dispos; 2002 Feb; 30(2):129-34. PubMed ID: 11792680
[TBL] [Abstract][Full Text] [Related]
51. Regioselectivity of human UDP-glucuronosyl-transferase 1A1 in the synthesis of flavonoid glucuronides determined by metal complexation and tandem mass spectrometry.
Davis BD; Brodbelt JS
J Am Soc Mass Spectrom; 2008 Feb; 19(2):246-56. PubMed ID: 18083528
[TBL] [Abstract][Full Text] [Related]
52. Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine.
Shiraga T; Yajima K; Suzuki K; Suzuki K; Hashimoto T; Iwatsubo T; Miyashita A; Usui T
Drug Metab Dispos; 2012 Feb; 40(2):276-82. PubMed ID: 22031623
[TBL] [Abstract][Full Text] [Related]
53. Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition.
Guo J; Zhou D; Grimm SW
J Pharm Biomed Anal; 2011 Jul; 55(5):964-71. PubMed ID: 21497036
[TBL] [Abstract][Full Text] [Related]
54. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of 3-hydroxydesloratadine.
Ghosal A; Yuan Y; Hapangama N; Su AD; Alvarez N; Chowdhury SK; Alton KB; Patrick JE; Zbaida S
Biopharm Drug Dispos; 2004 Sep; 25(6):243-52. PubMed ID: 15334623
[TBL] [Abstract][Full Text] [Related]
55. Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation.
Miners JO; Bowalgaha K; Elliot DJ; Baranczewski P; Knights KM
Drug Metab Dispos; 2011 Apr; 39(4):644-52. PubMed ID: 21245288
[TBL] [Abstract][Full Text] [Related]
56. Absolute quantification of human uridine-diphosphate glucuronosyl transferase (UGT) enzyme isoforms 1A1 and 1A6 by tandem LC-MS.
Fallon JK; Harbourt DE; Maleki SH; Kessler FK; Ritter JK; Smith PC
Drug Metab Lett; 2008 Aug; 2(3):210-22. PubMed ID: 19356096
[TBL] [Abstract][Full Text] [Related]
57. Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide.
Schwab N; Skopp G
Anal Bioanal Chem; 2014 Apr; 406(9-10):2325-32. PubMed ID: 24553666
[TBL] [Abstract][Full Text] [Related]
58. Glucuronidation of macelignan by human liver microsomes and expressed UGT enzymes: identification of UGT1A1 and 2B7 as the main contributing enzymes.
Liu H; Wu Z; Ma Z; Wu B
Biopharm Drug Dispos; 2014 Dec; 35(9):513-24. PubMed ID: 25099990
[TBL] [Abstract][Full Text] [Related]
59. Significantly decreased and more variable expression of major CYPs and UGTs in liver microsomes prepared from HBV-positive human hepatocellular carcinoma and matched pericarcinomatous tissues determined using an isotope label-free UPLC-MS/MS method.
Yan T; Gao S; Peng X; Shi J; Xie C; Li Q; Lu L; Wang Y; Zhou F; Liu Z; Hu M
Pharm Res; 2015 Mar; 32(3):1141-57. PubMed ID: 25288013
[TBL] [Abstract][Full Text] [Related]
60. Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies.
Chau N; Elliot DJ; Lewis BC; Burns K; Johnston MR; Mackenzie PI; Miners JO
J Pharmacol Exp Ther; 2014 Apr; 349(1):126-37. PubMed ID: 24459244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
